Asia
Valio’s consumer-packaged infant formulas have received an export permit from the Chinese authorities.
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
Al Ansari Exchange has donated USD 1 million to Gavi, the Vaccine Alliance to support the Alliance mission to create equal and improved access to new and underused vaccines for children living in the world’s poorest countries.
Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).
For Adjunctive Treatment of Partial Onset Seizures
For Dealing with Viruses and Bacteria! Antimicrobial Barrier that Lasts for 1 Week
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
This morning, Osaka, Japan-based Takeda struck deals with Memorial Sloan Kettering Cancer Center, Noile-Immune Biotech Inc. and Crescendo Biologics.
Novartis and Pfizer veteran Elizabeth Barrett will take over as the new president and chief executive officer of UroGen Pharma Ltd. Barrett, who most recently helmed Novartis Oncology, will take over as Ron Bentsur steps down from his role as CEO.
PRESS RELEASES